Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.


Player Avatar pchop123 (80.22) Submitted: 12/4/2012 10:22:30 AM : Underperform Start Price: $4.44 EXEL Score: -7.00

Not the horse you want to be riding right now

Featured Broker Partners